Lupin surges on entering into licensing agreement with Alvion
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 780.20, up by 2.20 points or 0.28% from its previous closing of Rs. 778.00 on the BSE.
The scrip opened at Rs. 772.00 and has touched a high and low of Rs. 786.00 and Rs. 771.50 respectively. So far 21341 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 678.65 on 07-Mar-2022.
Last one week high and low of the scrip stood at Rs. 798.90 and Rs. 736.35 respectively. The current market cap of the company is Rs. 35614.93 crore.
The promoters holding in the company stood at 46.81%, while Institutions and Non-Institutions held 40.39% and 12.79% respectively.
Lupin has entered into a licensing agreement with Alvion Pharmaceuticals P.C. (Alvion) to commercialize medicines for Cardiometabolic diseases in the Southeast Asia region.
The company is committed to providing new affordable treatment options to healthcare providers and patients. By commercializing cardiometabolic drugs in the Southeast Asian region, the company will play a significant role in improving the quality of healthcare and access to medicines.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
